Quantinno Capital Management LP Trims Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Quantinno Capital Management LP reduced its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 36.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 149,833 shares of the company's stock after selling 85,193 shares during the quarter. Quantinno Capital Management LP owned 0.12% of 10x Genomics worth $2,152,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TXG. Entropy Technologies LP boosted its holdings in shares of 10x Genomics by 285.6% during the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock valued at $540,000 after acquiring an additional 27,844 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock valued at $1,049,000 after buying an additional 49,468 shares during the last quarter. Alberta Investment Management Corp bought a new position in shares of 10x Genomics during the 4th quarter worth approximately $3,206,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of 10x Genomics in the 4th quarter worth about $326,000. Finally, Barclays PLC raised its stake in shares of 10x Genomics by 11.7% in the third quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after buying an additional 63,079 shares during the period. Institutional investors own 84.68% of the company's stock.

10x Genomics Price Performance

NASDAQ TXG traded down $0.37 during trading hours on Monday, reaching $8.17. 1,798,143 shares of the company's stock traded hands, compared to its average volume of 2,389,815. The firm has a market cap of $1.01 billion, a PE ratio of -5.38 and a beta of 1.94. 10x Genomics, Inc. has a 52-week low of $6.78 and a 52-week high of $24.76. The firm has a 50-day simple moving average of $8.59 and a 200 day simple moving average of $12.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The business's revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.50) EPS. Sell-side analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TXG has been the subject of several recent analyst reports. Barclays reduced their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Citigroup lowered their target price on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Leerink Partnrs cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. The Goldman Sachs Group cut their price target on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. Finally, Stephens reaffirmed an "overweight" rating and set a $14.00 price objective on shares of 10x Genomics in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $15.81.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.